GB9120304D0 - Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor - Google Patents

Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor

Info

Publication number
GB9120304D0
GB9120304D0 GB919120304A GB9120304A GB9120304D0 GB 9120304 D0 GB9120304 D0 GB 9120304D0 GB 919120304 A GB919120304 A GB 919120304A GB 9120304 A GB9120304 A GB 9120304A GB 9120304 D0 GB9120304 D0 GB 9120304D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
compositions containing
stimulating factor
colony stimulating
macrophage colony
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919120304A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL
Priority to GB919120304A priority Critical patent/GB9120304D0/en
Publication of GB9120304D0 publication Critical patent/GB9120304D0/en
Priority to PCT/EP1992/002084 priority patent/WO1993005799A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
GB919120304A 1991-09-24 1991-09-24 Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor Pending GB9120304D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB919120304A GB9120304D0 (en) 1991-09-24 1991-09-24 Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
PCT/EP1992/002084 WO1993005799A1 (en) 1991-09-24 1992-09-10 Lyophilized stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919120304A GB9120304D0 (en) 1991-09-24 1991-09-24 Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor

Publications (1)

Publication Number Publication Date
GB9120304D0 true GB9120304D0 (en) 1991-11-06

Family

ID=10701880

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919120304A Pending GB9120304D0 (en) 1991-09-24 1991-09-24 Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor

Country Status (2)

Country Link
GB (1) GB9120304D0 (en)
WO (1) WO1993005799A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE69724438T2 (en) * 1996-05-22 2004-06-09 Smithkline Beecham Corp. NON-PEPTIDIC G-CSF MIMETIC
EP0852951A1 (en) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
KR19990009888A (en) * 1997-07-12 1999-02-05 성재갑 Stable Solution Formulation of Colony Stimulating Factors
JP2000247903A (en) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
KR101208291B1 (en) 2003-04-04 2012-12-05 노파르티스 아게 High concentration antibody and protein formulations
TW200722518A (en) 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
AU2006256041B2 (en) * 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
WO2020002650A1 (en) * 2018-06-29 2020-01-02 Targovax Asa A formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA885101B (en) * 1987-07-17 1989-03-29 Schering Biotech Corp Human granulocyte macrophage colony stimulating factor and muteins thereof
JPH062664B2 (en) * 1987-11-17 1994-01-12 日本化薬株式会社 Stable multivitamin freeze-dried preparation
WO1989010407A1 (en) * 1988-04-29 1989-11-02 Genetics Institute, Inc. Homogeneous dimeric m-csf and storage stable formulations thereof
CA1339071C (en) * 1988-08-24 1997-07-29 Koichiro Tsuji Thrombus control agent
KR0137361B1 (en) * 1989-01-30 1998-04-25 스타이너 브이. 캔스타드 Treatment of leukocyte dysfuction with gm-csf
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor

Also Published As

Publication number Publication date
WO1993005799A1 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
GB9117361D0 (en) Oral dosage form
HU9303143D0 (en) Pharmaceutical compositions
ZA922834B (en) Pharmaceutical compositions
GB9120304D0 (en) Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
GB9108080D0 (en) Pharmaceutical composition
AP9200356A0 (en) Pharmaceutical composition
IL98179A0 (en) Pharmaceutical compositions containing phenylpropanolamine
IL102372A0 (en) Pharmaceutical composition containing a non-n-methyl-d-aspartate antagonist
GB2251617B (en) Pharmaceutical compositions containing substituted 3-hydroxypyridin-4-ones
GR3022416T3 (en) Programmed-release pharmaceutical compositions
GB9214757D0 (en) Pharmaceutical compositions
IL103226A0 (en) Pharmaceutical compositions containing calcitonin
IL97365A0 (en) Pharmaceutical compositions comprising a lymphokine
GB9221212D0 (en) Pharmaceutical compositions
IL101998A0 (en) 6-o-alkylelsamicin a derivatives and pharmaceutical compositions containing them
GB2252497B (en) Pharmaceutical composition
GB9200414D0 (en) Pharmaceutical compositions
GB9111477D0 (en) Pharmaceutical composition
GB9121989D0 (en) Pharmaceutical compositions
GB9108643D0 (en) Pharmaceutical compositions
GB9123423D0 (en) Pharmaceutical compositions
GB9121291D0 (en) Pharmaceutical compositions
GB9100464D0 (en) Pharmaceutical compositions
GB9119048D0 (en) Pharmaceutical compositions
GB9118481D0 (en) Pharmaceutical compositions